-
公开(公告)号：EP3558389A1
公开(公告)日：2019-10-30
申请号：EP17829033.4
申请日：2017-12-19
申请人： Novartis AG
-
公开(公告)号：EP2344473B1
公开(公告)日：2014-04-16
申请号：EP09782379.3
申请日：2009-08-31
申请人： Novartis AG
发明人： BURGER, Matthew , LAN, Jiong
IPC分类号： C07D401/12 , A61K31/517 , A61K31/4709 , A61P35/00
CPC分类号： C07D401/12
-
公开(公告)号：EP1984350A1
公开(公告)日：2008-10-29
申请号：EP07716906.8
申请日：2007-01-22
申请人： NOVARTIS AG
发明人： BURGER, Matthew , NI, Zhi-jie , PECCHI, Sabina , ATALLAH, Gordana , BARTULIS, Sarah , FRAZIER, Kelly , SMITH, Aaron , VERHAGEN, Joelle , ZHANG, Yanchen , WAGMAN, Allan , NG, Simon , PFISTER, Keith , POON, Daniel , LOUIE, Alicia , PICK, Teresa , BARSANTI, Paul , IWANOWICZ, Edwin , FANTL, Wendy , HENDRICKSON, Thomas , KNAPP, Mark , MERITT, Hanne , VOLIVA, Charles , WIESMANN, Marion , XIN, Xiahua
IPC分类号： C07D401/04 , C07D401/14 , C07D405/12 , C07D405/14 , C07D417/12 , A61K31/506 , A61P35/00
CPC分类号： C07D401/04 , C07D401/14 , C07D405/12 , C07D405/14 , C07D417/12
摘要： Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof ; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.
-
4.发明公开ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS 审中-公开ARYLSUBSTITUIERTE KONDENSIERTE BICYCLISCHE PYRIDAZINVERBINDUNGEN
公开(公告)号：EP2935270A1
公开(公告)日：2015-10-28
申请号：EP13818112.8
申请日：2013-12-17
申请人： Novartis AG
IPC分类号： C07D487/04 , A61K31/495 , A61P35/00
CPC分类号： C07D487/04 , A61K31/5025 , A61K45/06
摘要： The present invention provides a compound of formula (I) as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula (I), and pharmaceutical compositions comprising such compounds.
-
公开(公告)号：EP2681195A1
公开(公告)日：2014-01-08
申请号：EP12709966.1
申请日：2012-03-02
申请人： Novartis AG
发明人： BURGER, Matthew , NISHIGUCHI, Gisele , MACHAJEWSKI, Timothy, D. , RICO, Alice , SIMMONS, Robert, Lowell , SMITH, Aaron, R. , TAMEZ, Victoriano, Jr. , TANNER, Huw , WAN, Lifeng
IPC分类号： C07D213/75 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , A61K31/444 , A61P35/00 , A61P37/00
CPC分类号： C07D213/75 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14
摘要： The present invention provides compounds of Formula I: and related compounds as further described herein, and pharmaceutical compositions comprising these compounds. The invention further provides methods to use these compounds and compositions for treating disorders associated with undesired levels of Pim kinase activity, including cancers and autoimmune disorders.
-
公开(公告)号：EP2118087B1
公开(公告)日：2012-03-28
申请号：EP08729174.6
申请日：2008-02-06
申请人： Novartis AG
发明人： PECCHI, Sabina , NI, Zhi-jie , BURGER, Matthew , WAGMAN, Allan , ATALLAH, Gordana , BARTULIS, Sarah , NG, Simon , PFISTER, Keith, B. , SMITH, Aaron , ZHANG, Yanchen , MERRITT, Hanne , VOLIVA, Charles
IPC分类号： C07D401/04 , C07D401/14 , C07D405/14 , C07D413/14 , A61K31/5377 , A61P35/00
CPC分类号： C07D401/14 , C07D401/04 , C07D405/14 , C07D413/14
摘要： Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases, including proliferative diseases, inflammatory and obstructive airways diseases, allergic conditions, auutoimmune and cardiovascular diseases.
-
公开(公告)号：EP2342190A1
公开(公告)日：2011-07-13
申请号：EP09782373.6
申请日：2009-08-31
申请人： Novartis AG
发明人： BURGER, Matthew , LINDVALL, Mika
IPC分类号： C07D401/04 , C07D401/14 , C07D403/14 , C07D417/14 , C07D471/04 , A61K31/47
CPC分类号： C07D471/04 , C07D401/04 , C07D401/14 , C07D403/14 , C07D417/14
摘要： New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase- mediated disorder, such as cancer.
-
公开(公告)号：EP2262802A1
公开(公告)日：2010-12-22
申请号：EP09717066.6
申请日：2009-03-03
申请人： Novartis AG
IPC分类号： C07D417/12 , C07D417/14 , A61K31/4439 , A61P35/00
CPC分类号： C07D417/12 , C07D417/14
摘要： The present invention relates to new compounds of Formulas (I) and (II), their tautomers, stereoisomers and polymorphs, and pharmaceutically acceptable salts, esters, metabolites or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the inhibition of Pirn kinase activity and/or the prophylaxis or treatment of cancer.
-
公开(公告)号：EP3898697A2
公开(公告)日：2021-10-27
申请号：EP19856476.7
申请日：2019-12-18
申请人： Novartis AG
发明人： BURGER, Matthew , D'ALESSIO, Joseph, Anthony , FLEMING, Tony , RAUNIYAR, Vivek , ROBLES, Eusebio, Manchado
IPC分类号： C07K16/30 , A61K39/395
-
公开(公告)号：EP3299367A1
公开(公告)日：2018-03-28
申请号：EP17190132.5
申请日：2014-03-13
申请人： Novartis AG
发明人： AVERSA, Robert John , BARSANTI, Paul Andrew , BURGER, Matthew , DILLON, Michael Patrick , DIPESA, Alan , HU, Cheng , LOU, Yan , NISHIGUCHI, Gisele , PAN, Yue , POLYAKOV, Valery , RAMURTHY, Savithri , RICO, Alice , SETTI, Lina , SMITH, Aaron , SUBRAMANIAN, Sharadha , TAFT, Benjamin , TANNER, Huw , WAN, Lifeng , YUSUFF, Naeem
IPC分类号： C07D403/12
摘要： The present invention provides compounds of Formula (I)
as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.摘要翻译： 本发明提供如本文所述的式（I）的化合物及其盐，以及这些化合物用于治疗与Raf激酶活性相关的病症的治疗用途。 本发明进一步提供了包含这些化合物的药物组合物，以及包含这些化合物和治疗剂的组合物。
-
-
-
-
-
-
-
-
-
搜索结果
24 条记录 (耗时 0.025 秒)
